Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Regulatory / FDA CRL for Unicycive OLC NDA
Regulatory regulatory setback

FDA CRL for Unicycive OLC NDA

Analysis based on 6 articles · First reported Jun 30, 2026 · Last updated Jul 15, 2026

Sentiment
-30
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Unicycive's stock dropped sharply on the news, reflecting investor disappointment over the delay. The CRL does not affect the drug's safety profile but prolongs uncertainty until the manufacturing issue is resolved.

Biotechnology Pharmaceuticals
Event Summary

Unicycive Therapeutics received a Complete Response Letter (CRL) from the FDA regarding its resubmitted New Drug Application for oxylanthanum carbonate (OLC), a treatment for hyperphosphatemia in chronic kidney disease patients on dialysis. The CRL is based on unresolved manufacturing deficiencies at a third-party vendor, which the FDA has not yet inspected. No concerns were raised about clinical efficacy or safety, and no additional data was requested. Labeling discussions are ongoing. The stock fell 45.59% following the announcement.

Key Actions
100 United States — Food and Drug Administration issued Complete Response Letter Unicycive Therapeutics
80 Unicycive Therapeutics resubmitted NDA United States — Food and Drug Administration
50 Unicycive Therapeutics held Type A meeting United States — Food and Drug Administration
30 United States — Food and Drug Administration provided label feedback Unicycive Therapeutics
Entities Involved
stock
Unicycive Therapeutics
Unicycive received a second CRL for its lead drug OLC, causing a 45.59% stock decline. The company must resolve third-party manufacturing deficiencies before resubmission.
Importance 100.0 Sentiment -60.0
govactor
United States — Food and Drug Administration
The FDA issued a CRL based on manufacturing deficiencies at a third-party vendor, without raising efficacy or safety concerns. It continues labeling discussions with Unicycive.
Importance 80.0 Sentiment 0.0
per
Rishabh Gupta
As CEO, Rishabh Gupta expressed confidence in OLC's efficacy and safety, and optimism about resolving the manufacturing issue and resubmitting the NDA.
Importance 30.0 Sentiment -30.0
Relationships
Unicycive Therapeutics related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.